Robert E. Hoffman - 29 May 2025 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
02 Jun 2025, 16:09:32 UTC
Prior SEC filing
22 May 2025
Next SEC filing
12 Jun 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Sheldon L. Koenig, by power of attorney

Key filing fact

Robert E. Hoffman filed Form 4 for Esperion Therapeutics, Inc. (ESPR) on 02 Jun 2025.

Key facts

  • This page summarizes Robert E. Hoffman's Form 4 filing for Esperion Therapeutics, Inc. (ESPR).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 02 Jun 2025, 16:09.

Change

  • Previous filing in this sequence was filed on 22 May 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001166288 Primary reporting owner

Hoffman Robert E.

Relationship
Director
Address
C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR
Signature
/s/ Sheldon L. Koenig, by power of attorney
Signature date
02 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ESPR transaction

Common Stock

Award

Transaction value
$0
Shares
+5,280
Change %
Price
$0.000000
Shares after
5,280
Date
29 May 2025
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ESPR transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+7,040
Change %
Price
$0.000000
Shares after
7,040
Date
29 May 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
7,040
Exercise price
$0.8700
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The awards vest in full on the earlier of (i) May 29, 2026 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .